
Nataliya Milman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5914663/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	CanVasc Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitides. Journal of Rheumatology, 2016, 43, 97-120.	2.0	66
2	Correlation of a multi-cytokine panel with clinical disease activity in patients with rheumatoid arthritis. Clinical Biochemistry, 2010, 43, 1309-1314.	1.9	46
3	Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis. Rheumatology International, 2018, 38, 675-682.	3.0	40
4	Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12. Journal of Rheumatology, 2015, 42, 2465-2469.	2.0	33
5	Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016. Journal of Rheumatology, 2017, 44, 1933-1937.	2.0	33
6	Current Status of Outcome Measure Development in Vasculitis. Journal of Rheumatology, 2014, 41, 593-598.	2.0	31
7	CanVasc Consensus Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitis: 2020 Update. Journal of Rheumatology, 2021, 48, 555-566.	2.0	27
8	OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody–associated Vasculitis. Journal of Rheumatology, 2017, 44, 1529-1535.	2.0	25
9	Health-related quality of life in ANCA-associated vasculitis and item generation for a disease-specific patient-reported outcome measure. Patient Related Outcome Measures, 2018, Volume 9, 17-34.	1.2	24
10	Update on Outcome Measure Development in Large-vessel Vasculitis: Report from OMERACT 2018. Journal of Rheumatology, 2019, 46, 1198-1201.	2.0	24
11	Exploration, Development, and Validation of Patient-reported Outcomes in Antineutrophil Cytoplasmic Antibody–associated Vasculitis Using the OMERACT Process. Journal of Rheumatology, 2015, 42, 2204-2209.	2.0	22
12	Efficacy of leflunomide in the treatment of vasculitis. Clinical and Experimental Rheumatology, 2021, 39, 114-118.	0.8	14
13	CanVasc Recommendations for the Management of Antineutrophil Cytoplasm Antibody (ANCA)-Associated Vasculitides – Executive Summary. Canadian Journal of Kidney Health and Disease, 2015, 2, 78.	1.1	12
14	Association of anti-neutrophil cytoplasmic antibody-associated vasculitis and cardiovascular events: a population-based cohort study. CKJ: Clinical Kidney Journal, 2022, 15, 681-692.	2.9	10
15	Mapping of the Outcome Measures in Rheumatology Core Set for Antineutrophil Cytoplasmic Antibodyâ€Associated Vasculitis to the International Classification of Function, Disability and Health. Arthritis Care and Research, 2015, 67, 255-263.	3.4	9
16	An OMERACT Initiative Toward Consensus to Identify and Characterize Candidate Contextual Factors: Report from the Contextual Factors Working Group. Journal of Rheumatology, 2017, 44, 1734-1739.	2.0	9
17	A Case of Scurvy—Uncommon Disease—Presenting as Panniculitis, Purpura, and Oligoarthritis. Journal of Cutaneous Medicine and Surgery, 2016, 20, 592-595.	1.2	8
18	Cutaneous vasculopathy associated with cocaine use. Arthritis Care and Research, 2011, 63, 1195-1202.	3.4	7

NATALIYA MILMAN

#	Article	IF	CITATIONS
19	Development of Canadian Recommendations for the Management of ANCA-Associated Vasculitides: Results of the National Needs Assessment Questionnaire. Open Rheumatology Journal, 2015, 9, 16-20.	0.2	7
20	Updating OMERACT Core Set of Domains for ANCA-associated Vasculitis: Patient Perspective Using the International Classification of Function, Disability, and Health. Journal of Rheumatology, 2019, 46, 1415-1420.	2.0	7
21	A case series of surgically diagnosed idiopathic aortitis in a Canadian centre: a retrospective study. CMAJ Open, 2017, 5, E483-E487.	2.4	6
22	Variations in the clinical practice of physicians managing Takayasu arteritis: a nationwide survey. Open Access Rheumatology: Research and Reviews, 2017, Volume 9, 91-99.	1.6	6
23	Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis. Journal of Rheumatology, 2019, 46, 928-934.	2.0	6
24	Health-related outcomes of importance to patients with Takayasu's arteritis. Clinical and Experimental Rheumatology, 2018, 36 Suppl 111, 51-57.	0.8	6
25	Diagnostic outcome and indications for testing in patients with positive ANCA at a Canadian tertiary care centre. Rheumatology International, 2018, 38, 641-647.	3.0	4
26	Mononeuritis multiplex associated with minocycline in an adolescent. Muscle and Nerve, 2017, 56, E33-E35.	2.2	3
27	Characteristics and outcomes in a prospective cohort of patients with histologically diagnosed aortitis. Rheumatology Advances in Practice, 2019, 3, rky051.	0.7	3
28	Efficacy of leflunomide in the treatment of vasculitis. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 114-118.	0.8	3
29	Factors affecting patient satisfaction with outpatient rheumatology phoneÂvisits during the COVID-19 pandemic. Clinical Rheumatology, 2022, 41, 2839-2844.	2.2	2
30	P1_164 Assessing Canadian Practice Patterns Regarding Idiopathic Aortitis. Rheumatology, 2017, 56, iii95-iii97.	1.9	0